International Eye Science 2020;20(4):603-606
doi:10.3980/j.issn.1672-5123.2020.4.05
Research on the CP-RNFL thickness and optic nerve head and macular parameters differences between ocular hypertension patients with different CCT and normal subjects using 3D-OCT
Zhou Zhou 1
Affiliations
Keywords
ocular hypertension; optic disc; macular; retinal nerve fiber layer; optical coherence tomography
Country
China
Language
Chinese
Abstract
AIM: To compare the differences of CP-RNFL, optic nerve head(ONH)and macular parameters between ocular hypertension(OHT)patients with different central corneal thickness(CCT)and normal subjects using three dimensional optical coherence tomography(3D-OCT).
METHODS: This is a prospective study including 124 eyes of 77 OHT patients classified as group 1(CCT<555μm)including 38 eyes of 25 patients, group 2(CCT 555-590μm)including 44 eyes of 26 patients and group 3(CCT>590μm)including 42 eyes of 26 patients according to CCT. Totally 124 eyes of 77 normal healthy subjects, matching patients with age and gender, were divided into group four. The CP-RNFL thickness,optic nerve head and macular parameters were measured by 3D-OCT. There were no significant difference in gender, age between four groups and in intraocular pressure among three OHT patients groups.
RESULTS: The optic rim area was significantly smaller in group one than in other three groups, and the thickness of inferior CP-RNFL was significantly thinner than group two and group three, while the thickness of the temporal inner ring of macular was thinner than group three. All the thickness of the central fovea, macular center 1mm, the temporal inner ring of macular in OHT patients were significantly thinner than healthy subjects. The CCT and the rim area in OHT patients were significantly positively correlated.
CONCLUSION: The OHT patients are considered to be different from normal persons in optic nerve head and macular parameters though the parameters are still in normal range. CCT<555μm may be a risk factor of OHT patients converting to POAG, so we should pay more attention to following up these patients and intervention in time.
备案号: 11010502037788, 京ICP备10218182号-8)